Bio-Bridge-Science Inc. CEO Dr. Liang Qiao Featured in CEOcast Interview.OAK BROOK, Ill. -- Bio-Bridge-Science Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :BGES) announced that CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Dr. Liang Qiao is featured in an interview with CEOcast. The topics of discussion include the company's unique technology platform and its promising new HIV vaccine. Dr. Qiao also elaborates upon Bio-Bridge Science's plans and prospects for the upcoming year. The interview is available through CEOcast and can now be heard at www.ceocast.com in the latest interviews section. About Bio-Bridge Science: Bio-Bridge Science is a biotechnology firm focused on the development of vaccines with broad therapeutic and preventive applications. Through its wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. in Beijing, Bio-Bridge is developing a promising new HIV Vaccine, that is expected to enter clinical trials this year in China. The vaccine, based on exclusive technology co-developed by CEO Liang Qiao, an associate professor at Loyola University Chicago's Strich School of Medicine, targets infection in mucosal tissues, the first type of tissue attacked by HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. . The Chinese government, mindful of the rapid expansion of AIDS in China has, through the "Green Mile Policy" acted to expedite the approval of domestically produced HIV Vaccines and has dramatically increased its spending on AIDS-related research. In accordance with this policy, Bio-Bridge expects to bring its therapeutic HIV Vaccine A therapeutic HIV vaccine is a vaccine that when used provides immunity to HIV and the resultant AIDS condition. An effective HIV vaccine has been sought in medical research since the mid-1980s, although progress has been made only relatively recently. to market as early as 2008, far in advance of many other HIV Vaccines currently in development. Bio-Bridge is currently constructing a new $3 million state-of-the-art GMP GMP (guanosine monophosphate): see guanine. research and manufacturing facility in Beijing, which is expected to be completed by mid-year. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion